nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftriaxone—SLC22A8—nephron—kidney cancer	0.0257	0.128	CbGeAlD
Ceftriaxone—SLC22A8—urine—kidney cancer	0.0206	0.103	CbGeAlD
Ceftriaxone—GLUL—Amino acid synthesis and interconversion (transamination)—CCBL1—kidney cancer	0.0124	0.243	CbGpPWpGaD
Ceftriaxone—SLC22A11—nephron tubule—kidney cancer	0.00985	0.0491	CbGeAlD
Ceftriaxone—GLUL—nephron tubule—kidney cancer	0.00934	0.0466	CbGeAlD
Ceftriaxone—SLC22A6—nephron tubule—kidney cancer	0.00928	0.0463	CbGeAlD
Ceftriaxone—SLC22A11—renal system—kidney cancer	0.00895	0.0447	CbGeAlD
Ceftriaxone—SLC22A11—kidney—kidney cancer	0.00865	0.0432	CbGeAlD
Ceftriaxone—GLUL—renal system—kidney cancer	0.00849	0.0424	CbGeAlD
Ceftriaxone—SLC22A11—cortex of kidney—kidney cancer	0.00843	0.042	CbGeAlD
Ceftriaxone—GLUL—kidney—kidney cancer	0.00821	0.041	CbGeAlD
Ceftriaxone—GLUL—cortex of kidney—kidney cancer	0.008	0.0399	CbGeAlD
Ceftriaxone—SLC22A6—cortex of kidney—kidney cancer	0.00794	0.0396	CbGeAlD
Ceftriaxone—SLC15A1—nephron tubule—kidney cancer	0.00772	0.0385	CbGeAlD
Ceftriaxone—GLUL—gonad—kidney cancer	0.00762	0.038	CbGeAlD
Ceftriaxone—SLC15A1—renal system—kidney cancer	0.00702	0.035	CbGeAlD
Ceftriaxone—SLC15A1—kidney—kidney cancer	0.00679	0.0339	CbGeAlD
Ceftriaxone—SLC22A8—nephron tubule—kidney cancer	0.00556	0.0277	CbGeAlD
Ceftriaxone—SLC22A8—renal system—kidney cancer	0.00505	0.0252	CbGeAlD
Ceftriaxone—SLC22A8—kidney—kidney cancer	0.00488	0.0244	CbGeAlD
Ceftriaxone—SLC15A2—nephron tubule—kidney cancer	0.00483	0.0241	CbGeAlD
Ceftriaxone—SLC22A8—cortex of kidney—kidney cancer	0.00475	0.0237	CbGeAlD
Ceftriaxone—SLC15A2—renal system—kidney cancer	0.00439	0.0219	CbGeAlD
Ceftriaxone—SLC15A2—kidney—kidney cancer	0.00424	0.0212	CbGeAlD
Ceftriaxone—SLC15A2—cortex of kidney—kidney cancer	0.00413	0.0206	CbGeAlD
Ceftriaxone—GLUL—Amino acid and derivative metabolism—CCBL1—kidney cancer	0.00173	0.0338	CbGpPWpGaD
Ceftriaxone—GLUL—TNF alpha Signaling Pathway—APAF1—kidney cancer	0.0015	0.0292	CbGpPWpGaD
Ceftriaxone—SLC22A11—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A3—kidney cancer	0.000962	0.0188	CbGpPWpGaD
Ceftriaxone—ALB—HDL-mediated lipid transport—SCARB1—kidney cancer	0.000822	0.016	CbGpPWpGaD
Ceftriaxone—SLC15A2—Amino acid and oligopeptide SLC transporters—SLC5A5—kidney cancer	0.000809	0.0158	CbGpPWpGaD
Ceftriaxone—Haemorrhage—Paclitaxel—kidney cancer	0.000776	0.00104	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Erlotinib—kidney cancer	0.000775	0.00104	CcSEcCtD
Ceftriaxone—Sweating increased—Capecitabine—kidney cancer	0.000775	0.00104	CcSEcCtD
Ceftriaxone—Infection—Dactinomycin—kidney cancer	0.000772	0.00103	CcSEcCtD
Ceftriaxone—Vaginal infection—Doxorubicin—kidney cancer	0.000772	0.00103	CcSEcCtD
Ceftriaxone—Aplastic anaemia—Doxorubicin—kidney cancer	0.000767	0.00103	CcSEcCtD
Ceftriaxone—Leukopenia—Vincristine—kidney cancer	0.000761	0.00102	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Dactinomycin—kidney cancer	0.00076	0.00102	CcSEcCtD
Ceftriaxone—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC5A5—kidney cancer	0.000751	0.0147	CbGpPWpGaD
Ceftriaxone—Dyspepsia—Sorafenib—kidney cancer	0.000751	0.001	CcSEcCtD
Ceftriaxone—Abdominal pain—Erlotinib—kidney cancer	0.000749	0.001	CcSEcCtD
Ceftriaxone—Body temperature increased—Erlotinib—kidney cancer	0.000749	0.001	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Gemcitabine—kidney cancer	0.000748	0.001	CcSEcCtD
Ceftriaxone—Anaemia—Gemcitabine—kidney cancer	0.000746	0.000996	CcSEcCtD
Ceftriaxone—Neutropenia—Capecitabine—kidney cancer	0.000744	0.000994	CcSEcCtD
Ceftriaxone—Nausea—Pazopanib—kidney cancer	0.000739	0.000987	CcSEcCtD
Ceftriaxone—Paraesthesia—Sunitinib—kidney cancer	0.000737	0.000985	CcSEcCtD
Ceftriaxone—Convulsion—Vincristine—kidney cancer	0.000737	0.000984	CcSEcCtD
Ceftriaxone—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A3—kidney cancer	0.000734	0.0143	CbGpPWpGaD
Ceftriaxone—Erythema multiforme—Paclitaxel—kidney cancer	0.000733	0.00098	CcSEcCtD
Ceftriaxone—Pain—Sorafenib—kidney cancer	0.000729	0.000974	CcSEcCtD
Ceftriaxone—Malaise—Gemcitabine—kidney cancer	0.000727	0.000972	CcSEcCtD
Ceftriaxone—Hypersensitivity—Vinblastine—kidney cancer	0.000726	0.000971	CcSEcCtD
Ceftriaxone—Hypersensitivity—Everolimus—kidney cancer	0.000724	0.000967	CcSEcCtD
Ceftriaxone—Dyspepsia—Sunitinib—kidney cancer	0.000722	0.000965	CcSEcCtD
Ceftriaxone—Leukopenia—Gemcitabine—kidney cancer	0.000722	0.000965	CcSEcCtD
Ceftriaxone—Flushing—Paclitaxel—kidney cancer	0.00072	0.000962	CcSEcCtD
Ceftriaxone—Hypertonia—Doxorubicin—kidney cancer	0.000716	0.000957	CcSEcCtD
Ceftriaxone—Stevens-Johnson syndrome—Capecitabine—kidney cancer	0.000703	0.00094	CcSEcCtD
Ceftriaxone—Pain—Sunitinib—kidney cancer	0.000702	0.000938	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Sorafenib—kidney cancer	0.000697	0.000932	CcSEcCtD
Ceftriaxone—Renal failure—Capecitabine—kidney cancer	0.000697	0.000932	CcSEcCtD
Ceftriaxone—Chills—Paclitaxel—kidney cancer	0.000696	0.00093	CcSEcCtD
Ceftriaxone—Pruritus—Everolimus—kidney cancer	0.000695	0.000929	CcSEcCtD
Ceftriaxone—Oedema—Vincristine—kidney cancer	0.000694	0.000927	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Vincristine—kidney cancer	0.000694	0.000927	CcSEcCtD
Ceftriaxone—Jaundice—Capecitabine—kidney cancer	0.000691	0.000924	CcSEcCtD
Ceftriaxone—Stomatitis—Capecitabine—kidney cancer	0.000691	0.000924	CcSEcCtD
Ceftriaxone—Infection—Vincristine—kidney cancer	0.000689	0.000921	CcSEcCtD
Ceftriaxone—Phlebitis—Doxorubicin—kidney cancer	0.000689	0.00092	CcSEcCtD
Ceftriaxone—GLUL—Neuronal System—KCNMA1—kidney cancer	0.000687	0.0134	CbGpPWpGaD
Ceftriaxone—Thrombophlebitis—Doxorubicin—kidney cancer	0.000685	0.000916	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Vincristine—kidney cancer	0.000679	0.000908	CcSEcCtD
Ceftriaxone—Hepatic function abnormal—Doxorubicin—kidney cancer	0.000679	0.000907	CcSEcCtD
Ceftriaxone—Discomfort—Gemcitabine—kidney cancer	0.000678	0.000907	CcSEcCtD
Ceftriaxone—Urticaria—Sorafenib—kidney cancer	0.000677	0.000905	CcSEcCtD
Ceftriaxone—Haematuria—Capecitabine—kidney cancer	0.000676	0.000904	CcSEcCtD
Ceftriaxone—Diarrhoea—Vinblastine—kidney cancer	0.000675	0.000902	CcSEcCtD
Ceftriaxone—Body temperature increased—Sorafenib—kidney cancer	0.000674	0.000901	CcSEcCtD
Ceftriaxone—Abdominal pain—Sorafenib—kidney cancer	0.000674	0.000901	CcSEcCtD
Ceftriaxone—Diarrhoea—Everolimus—kidney cancer	0.000672	0.000898	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Sunitinib—kidney cancer	0.000671	0.000897	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Vincristine—kidney cancer	0.000671	0.000896	CcSEcCtD
Ceftriaxone—Pruritus—Erlotinib—kidney cancer	0.000671	0.000896	CcSEcCtD
Ceftriaxone—Epistaxis—Capecitabine—kidney cancer	0.000669	0.000894	CcSEcCtD
Ceftriaxone—Flatulence—Paclitaxel—kidney cancer	0.000665	0.000889	CcSEcCtD
Ceftriaxone—Pain—Dactinomycin—kidney cancer	0.000664	0.000888	CcSEcCtD
Ceftriaxone—GLUL—Transmission across Chemical Synapses—ACHE—kidney cancer	0.000664	0.013	CbGpPWpGaD
Ceftriaxone—Agranulocytosis—Capecitabine—kidney cancer	0.000662	0.000884	CcSEcCtD
Ceftriaxone—Dysgeusia—Paclitaxel—kidney cancer	0.000661	0.000884	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Gemcitabine—kidney cancer	0.000658	0.00088	CcSEcCtD
Ceftriaxone—Oedema—Gemcitabine—kidney cancer	0.000658	0.00088	CcSEcCtD
Ceftriaxone—Infection—Gemcitabine—kidney cancer	0.000654	0.000874	CcSEcCtD
Ceftriaxone—Dizziness—Vinblastine—kidney cancer	0.000652	0.000871	CcSEcCtD
Ceftriaxone—Dizziness—Everolimus—kidney cancer	0.00065	0.000868	CcSEcCtD
Ceftriaxone—Abdominal pain—Sunitinib—kidney cancer	0.000649	0.000867	CcSEcCtD
Ceftriaxone—Body temperature increased—Sunitinib—kidney cancer	0.000649	0.000867	CcSEcCtD
Ceftriaxone—Diarrhoea—Erlotinib—kidney cancer	0.000648	0.000867	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Gemcitabine—kidney cancer	0.000645	0.000861	CcSEcCtD
Ceftriaxone—GLUL—Amino acid and derivative metabolism—PSMD7—kidney cancer	0.000641	0.0125	CbGpPWpGaD
Ceftriaxone—Feeling abnormal—Dactinomycin—kidney cancer	0.00064	0.000855	CcSEcCtD
Ceftriaxone—Haemoglobin—Capecitabine—kidney cancer	0.00064	0.000855	CcSEcCtD
Ceftriaxone—Haemorrhage—Capecitabine—kidney cancer	0.000637	0.000851	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Gemcitabine—kidney cancer	0.000636	0.00085	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000635	0.000849	CcSEcCtD
Ceftriaxone—Dermatitis exfoliative—Doxorubicin—kidney cancer	0.000629	0.00084	CcSEcCtD
Ceftriaxone—Hypersensitivity—Sorafenib—kidney cancer	0.000628	0.000839	CcSEcCtD
Ceftriaxone—Vomiting—Vinblastine—kidney cancer	0.000627	0.000838	CcSEcCtD
Ceftriaxone—Dizziness—Erlotinib—kidney cancer	0.000627	0.000838	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Paclitaxel—kidney cancer	0.000627	0.000837	CcSEcCtD
Ceftriaxone—ALB—FOXA2 and FOXA3 transcription factor networks—HNF1A—kidney cancer	0.000625	0.0122	CbGpPWpGaD
Ceftriaxone—Vomiting—Everolimus—kidney cancer	0.000625	0.000835	CcSEcCtD
Ceftriaxone—Anaemia—Paclitaxel—kidney cancer	0.000624	0.000834	CcSEcCtD
Ceftriaxone—Renal impairment—Doxorubicin—kidney cancer	0.000623	0.000833	CcSEcCtD
Ceftriaxone—Paraesthesia—Vincristine—kidney cancer	0.000623	0.000833	CcSEcCtD
Ceftriaxone—Agitation—Paclitaxel—kidney cancer	0.000621	0.000829	CcSEcCtD
Ceftriaxone—Rash—Everolimus—kidney cancer	0.000619	0.000828	CcSEcCtD
Ceftriaxone—Dermatitis—Everolimus—kidney cancer	0.000619	0.000827	CcSEcCtD
Ceftriaxone—Headache—Vinblastine—kidney cancer	0.000618	0.000825	CcSEcCtD
Ceftriaxone—Headache—Everolimus—kidney cancer	0.000615	0.000822	CcSEcCtD
Ceftriaxone—Abdominal pain—Dactinomycin—kidney cancer	0.000614	0.000821	CcSEcCtD
Ceftriaxone—Body temperature increased—Dactinomycin—kidney cancer	0.000614	0.000821	CcSEcCtD
Ceftriaxone—Anaphylactoid reaction—Doxorubicin—kidney cancer	0.000613	0.000819	CcSEcCtD
Ceftriaxone—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A3—kidney cancer	0.000612	0.012	CbGpPWpGaD
Ceftriaxone—Malaise—Paclitaxel—kidney cancer	0.000609	0.000814	CcSEcCtD
Ceftriaxone—Leukopenia—Paclitaxel—kidney cancer	0.000604	0.000808	CcSEcCtD
Ceftriaxone—Hypersensitivity—Sunitinib—kidney cancer	0.000604	0.000808	CcSEcCtD
Ceftriaxone—Pruritus—Sorafenib—kidney cancer	0.000603	0.000806	CcSEcCtD
Ceftriaxone—Vomiting—Erlotinib—kidney cancer	0.000603	0.000805	CcSEcCtD
Ceftriaxone—Erythema multiforme—Capecitabine—kidney cancer	0.000602	0.000804	CcSEcCtD
Ceftriaxone—GLUL—Amino acid and derivative metabolism—SLC5A5—kidney cancer	0.0006	0.0117	CbGpPWpGaD
Ceftriaxone—Rash—Erlotinib—kidney cancer	0.000598	0.000799	CcSEcCtD
Ceftriaxone—Dermatitis—Erlotinib—kidney cancer	0.000597	0.000798	CcSEcCtD
Ceftriaxone—Palpitations—Paclitaxel—kidney cancer	0.000597	0.000798	CcSEcCtD
Ceftriaxone—Headache—Erlotinib—kidney cancer	0.000594	0.000793	CcSEcCtD
Ceftriaxone—Pain—Vincristine—kidney cancer	0.000593	0.000793	CcSEcCtD
Ceftriaxone—Paraesthesia—Gemcitabine—kidney cancer	0.000591	0.00079	CcSEcCtD
Ceftriaxone—Flushing—Capecitabine—kidney cancer	0.000591	0.00079	CcSEcCtD
Ceftriaxone—Nausea—Vinblastine—kidney cancer	0.000586	0.000783	CcSEcCtD
Ceftriaxone—Convulsion—Paclitaxel—kidney cancer	0.000585	0.000782	CcSEcCtD
Ceftriaxone—Nausea—Everolimus—kidney cancer	0.000583	0.00078	CcSEcCtD
Ceftriaxone—Diarrhoea—Sorafenib—kidney cancer	0.000583	0.00078	CcSEcCtD
Ceftriaxone—Pruritus—Sunitinib—kidney cancer	0.00058	0.000776	CcSEcCtD
Ceftriaxone—GLUL—Transmission across Chemical Synapses—BCHE—kidney cancer	0.000578	0.0113	CbGpPWpGaD
Ceftriaxone—Hypersensitivity—Dactinomycin—kidney cancer	0.000572	0.000765	CcSEcCtD
Ceftriaxone—Chills—Capecitabine—kidney cancer	0.000571	0.000763	CcSEcCtD
Ceftriaxone—Discomfort—Paclitaxel—kidney cancer	0.000568	0.000759	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Vincristine—kidney cancer	0.000567	0.000758	CcSEcCtD
Ceftriaxone—Dizziness—Sorafenib—kidney cancer	0.000564	0.000753	CcSEcCtD
Ceftriaxone—Pain—Gemcitabine—kidney cancer	0.000563	0.000752	CcSEcCtD
Ceftriaxone—Nausea—Erlotinib—kidney cancer	0.000563	0.000752	CcSEcCtD
Ceftriaxone—Diarrhoea—Sunitinib—kidney cancer	0.000561	0.00075	CcSEcCtD
Ceftriaxone—Ataxia—Doxorubicin—kidney cancer	0.000558	0.000745	CcSEcCtD
Ceftriaxone—Blood creatinine increased—Doxorubicin—kidney cancer	0.000556	0.000743	CcSEcCtD
Ceftriaxone—Oedema—Paclitaxel—kidney cancer	0.000551	0.000737	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Paclitaxel—kidney cancer	0.000551	0.000737	CcSEcCtD
Ceftriaxone—Body temperature increased—Vincristine—kidney cancer	0.000549	0.000733	CcSEcCtD
Ceftriaxone—Abdominal pain—Vincristine—kidney cancer	0.000549	0.000733	CcSEcCtD
Ceftriaxone—Infection—Paclitaxel—kidney cancer	0.000548	0.000732	CcSEcCtD
Ceftriaxone—Flatulence—Capecitabine—kidney cancer	0.000546	0.00073	CcSEcCtD
Ceftriaxone—Dysgeusia—Capecitabine—kidney cancer	0.000543	0.000725	CcSEcCtD
Ceftriaxone—Dizziness—Sunitinib—kidney cancer	0.000543	0.000725	CcSEcCtD
Ceftriaxone—Feeling abnormal—Gemcitabine—kidney cancer	0.000542	0.000725	CcSEcCtD
Ceftriaxone—Vomiting—Sorafenib—kidney cancer	0.000542	0.000724	CcSEcCtD
Ceftriaxone—Abdominal pain upper—Doxorubicin—kidney cancer	0.000542	0.000724	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Paclitaxel—kidney cancer	0.00054	0.000721	CcSEcCtD
Ceftriaxone—Rash—Sorafenib—kidney cancer	0.000538	0.000718	CcSEcCtD
Ceftriaxone—Dermatitis—Sorafenib—kidney cancer	0.000537	0.000718	CcSEcCtD
Ceftriaxone—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	0.000534	0.000714	CcSEcCtD
Ceftriaxone—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	0.000534	0.000714	CcSEcCtD
Ceftriaxone—Headache—Sorafenib—kidney cancer	0.000534	0.000714	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Paclitaxel—kidney cancer	0.000533	0.000712	CcSEcCtD
Ceftriaxone—Diarrhoea—Dactinomycin—kidney cancer	0.000531	0.00071	CcSEcCtD
Ceftriaxone—Vomiting—Sunitinib—kidney cancer	0.000522	0.000697	CcSEcCtD
Ceftriaxone—Body temperature increased—Gemcitabine—kidney cancer	0.00052	0.000695	CcSEcCtD
Ceftriaxone—Rash—Sunitinib—kidney cancer	0.000517	0.000691	CcSEcCtD
Ceftriaxone—Dermatitis—Sunitinib—kidney cancer	0.000517	0.000691	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Capecitabine—kidney cancer	0.000514	0.000687	CcSEcCtD
Ceftriaxone—Headache—Sunitinib—kidney cancer	0.000514	0.000687	CcSEcCtD
Ceftriaxone—Anaemia—Capecitabine—kidney cancer	0.000512	0.000685	CcSEcCtD
Ceftriaxone—Hypersensitivity—Vincristine—kidney cancer	0.000511	0.000683	CcSEcCtD
Ceftriaxone—GLUL—Neuronal System—ACHE—kidney cancer	0.000508	0.00992	CbGpPWpGaD
Ceftriaxone—Eosinophilia—Doxorubicin—kidney cancer	0.000508	0.000678	CcSEcCtD
Ceftriaxone—Nausea—Sorafenib—kidney cancer	0.000506	0.000677	CcSEcCtD
Ceftriaxone—Pancreatitis—Doxorubicin—kidney cancer	0.000503	0.000672	CcSEcCtD
Ceftriaxone—Malaise—Capecitabine—kidney cancer	0.0005	0.000668	CcSEcCtD
Ceftriaxone—Leukopenia—Capecitabine—kidney cancer	0.000496	0.000663	CcSEcCtD
Ceftriaxone—Paraesthesia—Paclitaxel—kidney cancer	0.000495	0.000661	CcSEcCtD
Ceftriaxone—Vomiting—Dactinomycin—kidney cancer	0.000494	0.00066	CcSEcCtD
Ceftriaxone—Palpitations—Capecitabine—kidney cancer	0.00049	0.000654	CcSEcCtD
Ceftriaxone—Rash—Dactinomycin—kidney cancer	0.00049	0.000654	CcSEcCtD
Ceftriaxone—Nausea—Sunitinib—kidney cancer	0.000487	0.000651	CcSEcCtD
Ceftriaxone—Dyspepsia—Paclitaxel—kidney cancer	0.000485	0.000648	CcSEcCtD
Ceftriaxone—Neutropenia—Doxorubicin—kidney cancer	0.000479	0.000641	CcSEcCtD
Ceftriaxone—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—kidney cancer	0.000477	0.0093	CbGpPWpGaD
Ceftriaxone—Diarrhoea—Vincristine—kidney cancer	0.000475	0.000635	CcSEcCtD
Ceftriaxone—ALB—Lipoprotein metabolism—SCARB1—kidney cancer	0.000472	0.00922	CbGpPWpGaD
Ceftriaxone—Pain—Paclitaxel—kidney cancer	0.000471	0.00063	CcSEcCtD
Ceftriaxone—Discomfort—Capecitabine—kidney cancer	0.000466	0.000623	CcSEcCtD
Ceftriaxone—Pruritus—Gemcitabine—kidney cancer	0.000466	0.000622	CcSEcCtD
Ceftriaxone—Nausea—Dactinomycin—kidney cancer	0.000461	0.000617	CcSEcCtD
Ceftriaxone—Dizziness—Vincristine—kidney cancer	0.000459	0.000613	CcSEcCtD
Ceftriaxone—GLUL—TNF alpha Signaling Pathway—RAF1—kidney cancer	0.000458	0.00895	CbGpPWpGaD
Ceftriaxone—Feeling abnormal—Paclitaxel—kidney cancer	0.000454	0.000607	CcSEcCtD
Ceftriaxone—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	0.000453	0.000606	CcSEcCtD
Ceftriaxone—Oedema—Capecitabine—kidney cancer	0.000452	0.000604	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000451	0.000602	CcSEcCtD
Ceftriaxone—Diarrhoea—Gemcitabine—kidney cancer	0.00045	0.000602	CcSEcCtD
Ceftriaxone—Renal failure—Doxorubicin—kidney cancer	0.000449	0.000601	CcSEcCtD
Ceftriaxone—Infection—Capecitabine—kidney cancer	0.000449	0.0006	CcSEcCtD
Ceftriaxone—Stomatitis—Doxorubicin—kidney cancer	0.000446	0.000595	CcSEcCtD
Ceftriaxone—Jaundice—Doxorubicin—kidney cancer	0.000446	0.000595	CcSEcCtD
Ceftriaxone—GLUL—Neuronal System—BCHE—kidney cancer	0.000443	0.00865	CbGpPWpGaD
Ceftriaxone—Thrombocytopenia—Capecitabine—kidney cancer	0.000443	0.000592	CcSEcCtD
Ceftriaxone—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—kidney cancer	0.000442	0.00863	CbGpPWpGaD
Ceftriaxone—Vomiting—Vincristine—kidney cancer	0.000441	0.00059	CcSEcCtD
Ceftriaxone—Urticaria—Paclitaxel—kidney cancer	0.000438	0.000585	CcSEcCtD
Ceftriaxone—Rash—Vincristine—kidney cancer	0.000438	0.000585	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Capecitabine—kidney cancer	0.000437	0.000584	CcSEcCtD
Ceftriaxone—Dermatitis—Vincristine—kidney cancer	0.000437	0.000584	CcSEcCtD
Ceftriaxone—SLC22A11—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	0.000437	0.00853	CbGpPWpGaD
Ceftriaxone—Haematuria—Doxorubicin—kidney cancer	0.000436	0.000582	CcSEcCtD
Ceftriaxone—Abdominal pain—Paclitaxel—kidney cancer	0.000436	0.000582	CcSEcCtD
Ceftriaxone—Body temperature increased—Paclitaxel—kidney cancer	0.000436	0.000582	CcSEcCtD
Ceftriaxone—Headache—Vincristine—kidney cancer	0.000435	0.000581	CcSEcCtD
Ceftriaxone—Epistaxis—Doxorubicin—kidney cancer	0.000431	0.000576	CcSEcCtD
Ceftriaxone—Agranulocytosis—Doxorubicin—kidney cancer	0.000427	0.00057	CcSEcCtD
Ceftriaxone—Vomiting—Gemcitabine—kidney cancer	0.000419	0.000559	CcSEcCtD
Ceftriaxone—Rash—Gemcitabine—kidney cancer	0.000415	0.000555	CcSEcCtD
Ceftriaxone—Dermatitis—Gemcitabine—kidney cancer	0.000415	0.000554	CcSEcCtD
Ceftriaxone—Haemoglobin—Doxorubicin—kidney cancer	0.000412	0.000551	CcSEcCtD
Ceftriaxone—Headache—Gemcitabine—kidney cancer	0.000412	0.000551	CcSEcCtD
Ceftriaxone—Nausea—Vincristine—kidney cancer	0.000412	0.000551	CcSEcCtD
Ceftriaxone—Haemorrhage—Doxorubicin—kidney cancer	0.00041	0.000548	CcSEcCtD
Ceftriaxone—Paraesthesia—Capecitabine—kidney cancer	0.000406	0.000543	CcSEcCtD
Ceftriaxone—Hypersensitivity—Paclitaxel—kidney cancer	0.000406	0.000543	CcSEcCtD
Ceftriaxone—SLC15A2—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	0.000404	0.00788	CbGpPWpGaD
Ceftriaxone—GLUL—TNF alpha Signaling Pathway—JUN—kidney cancer	0.0004	0.00781	CbGpPWpGaD
Ceftriaxone—Dyspepsia—Capecitabine—kidney cancer	0.000398	0.000532	CcSEcCtD
Ceftriaxone—GLUL—Metabolism—ACY1—kidney cancer	0.000398	0.00776	CbGpPWpGaD
Ceftriaxone—Nausea—Gemcitabine—kidney cancer	0.000391	0.000523	CcSEcCtD
Ceftriaxone—Pruritus—Paclitaxel—kidney cancer	0.00039	0.000521	CcSEcCtD
Ceftriaxone—Erythema multiforme—Doxorubicin—kidney cancer	0.000388	0.000519	CcSEcCtD
Ceftriaxone—Pain—Capecitabine—kidney cancer	0.000387	0.000517	CcSEcCtD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—RYR1—kidney cancer	0.000387	0.00755	CbGpPWpGaD
Ceftriaxone—Flushing—Doxorubicin—kidney cancer	0.000381	0.000509	CcSEcCtD
Ceftriaxone—Diarrhoea—Paclitaxel—kidney cancer	0.000377	0.000504	CcSEcCtD
Ceftriaxone—SLC15A1—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	0.000375	0.00732	CbGpPWpGaD
Ceftriaxone—Feeling abnormal—Capecitabine—kidney cancer	0.000373	0.000498	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Capecitabine—kidney cancer	0.00037	0.000494	CcSEcCtD
Ceftriaxone—Chills—Doxorubicin—kidney cancer	0.000368	0.000492	CcSEcCtD
Ceftriaxone—ALB—Binding and Uptake of Ligands by Scavenger Receptors—SCARB1—kidney cancer	0.000368	0.00718	CbGpPWpGaD
Ceftriaxone—Dizziness—Paclitaxel—kidney cancer	0.000364	0.000487	CcSEcCtD
Ceftriaxone—Urticaria—Capecitabine—kidney cancer	0.000359	0.00048	CcSEcCtD
Ceftriaxone—Body temperature increased—Capecitabine—kidney cancer	0.000358	0.000478	CcSEcCtD
Ceftriaxone—Abdominal pain—Capecitabine—kidney cancer	0.000358	0.000478	CcSEcCtD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—RYR1—kidney cancer	0.000357	0.00697	CbGpPWpGaD
Ceftriaxone—Flatulence—Doxorubicin—kidney cancer	0.000352	0.00047	CcSEcCtD
Ceftriaxone—Vomiting—Paclitaxel—kidney cancer	0.00035	0.000468	CcSEcCtD
Ceftriaxone—Dysgeusia—Doxorubicin—kidney cancer	0.00035	0.000468	CcSEcCtD
Ceftriaxone—Rash—Paclitaxel—kidney cancer	0.000348	0.000464	CcSEcCtD
Ceftriaxone—Dermatitis—Paclitaxel—kidney cancer	0.000347	0.000464	CcSEcCtD
Ceftriaxone—Headache—Paclitaxel—kidney cancer	0.000345	0.000461	CcSEcCtD
Ceftriaxone—GLUL—Metabolism—PDHB—kidney cancer	0.000338	0.0066	CbGpPWpGaD
Ceftriaxone—SLC22A8—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	0.000333	0.00651	CbGpPWpGaD
Ceftriaxone—Hypersensitivity—Capecitabine—kidney cancer	0.000333	0.000445	CcSEcCtD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—RYR1—kidney cancer	0.000332	0.00647	CbGpPWpGaD
Ceftriaxone—Ill-defined disorder—Doxorubicin—kidney cancer	0.000331	0.000443	CcSEcCtD
Ceftriaxone—GLUL—TNF alpha Signaling Pathway—MAPK3—kidney cancer	0.00033	0.00645	CbGpPWpGaD
Ceftriaxone—Anaemia—Doxorubicin—kidney cancer	0.00033	0.000441	CcSEcCtD
Ceftriaxone—Agitation—Doxorubicin—kidney cancer	0.000328	0.000439	CcSEcCtD
Ceftriaxone—Nausea—Paclitaxel—kidney cancer	0.000327	0.000438	CcSEcCtD
Ceftriaxone—Malaise—Doxorubicin—kidney cancer	0.000322	0.000431	CcSEcCtD
Ceftriaxone—Pruritus—Capecitabine—kidney cancer	0.00032	0.000428	CcSEcCtD
Ceftriaxone—Leukopenia—Doxorubicin—kidney cancer	0.00032	0.000427	CcSEcCtD
Ceftriaxone—GLUL—Metabolism—CCBL1—kidney cancer	0.000318	0.00621	CbGpPWpGaD
Ceftriaxone—Palpitations—Doxorubicin—kidney cancer	0.000316	0.000422	CcSEcCtD
Ceftriaxone—GLUL—TNF alpha Signaling Pathway—MAPK1—kidney cancer	0.000314	0.00614	CbGpPWpGaD
Ceftriaxone—ALB—Lipid and lipoprotein metabolism—SCARB1—kidney cancer	0.000314	0.00612	CbGpPWpGaD
Ceftriaxone—Convulsion—Doxorubicin—kidney cancer	0.00031	0.000414	CcSEcCtD
Ceftriaxone—Diarrhoea—Capecitabine—kidney cancer	0.000309	0.000414	CcSEcCtD
Ceftriaxone—ALB—Vitamin B12 Metabolism—SCARB1—kidney cancer	0.000309	0.00603	CbGpPWpGaD
Ceftriaxone—Discomfort—Doxorubicin—kidney cancer	0.0003	0.000402	CcSEcCtD
Ceftriaxone—Dizziness—Capecitabine—kidney cancer	0.000299	0.0004	CcSEcCtD
Ceftriaxone—GLUL—TNF alpha Signaling Pathway—KRAS—kidney cancer	0.000297	0.0058	CbGpPWpGaD
Ceftriaxone—GLUL—Transmission across Chemical Synapses—BRAF—kidney cancer	0.000295	0.00576	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—RYR1—kidney cancer	0.000295	0.00576	CbGpPWpGaD
Ceftriaxone—Anaphylactic shock—Doxorubicin—kidney cancer	0.000292	0.00039	CcSEcCtD
Ceftriaxone—Oedema—Doxorubicin—kidney cancer	0.000292	0.00039	CcSEcCtD
Ceftriaxone—Infection—Doxorubicin—kidney cancer	0.00029	0.000387	CcSEcCtD
Ceftriaxone—Vomiting—Capecitabine—kidney cancer	0.000288	0.000384	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Doxorubicin—kidney cancer	0.000285	0.000381	CcSEcCtD
Ceftriaxone—Rash—Capecitabine—kidney cancer	0.000285	0.000381	CcSEcCtD
Ceftriaxone—Dermatitis—Capecitabine—kidney cancer	0.000285	0.000381	CcSEcCtD
Ceftriaxone—Headache—Capecitabine—kidney cancer	0.000283	0.000379	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Doxorubicin—kidney cancer	0.000282	0.000377	CcSEcCtD
Ceftriaxone—SLC22A6—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	0.000278	0.00543	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PPAT—kidney cancer	0.000276	0.00538	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—GLIPR1—kidney cancer	0.000276	0.00538	CbGpPWpGaD
Ceftriaxone—Nausea—Capecitabine—kidney cancer	0.000269	0.000359	CcSEcCtD
Ceftriaxone—Paraesthesia—Doxorubicin—kidney cancer	0.000262	0.00035	CcSEcCtD
Ceftriaxone—Dyspepsia—Doxorubicin—kidney cancer	0.000257	0.000343	CcSEcCtD
Ceftriaxone—GLUL—Metabolism—FH—kidney cancer	0.000256	0.005	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—APRT—kidney cancer	0.000256	0.005	CbGpPWpGaD
Ceftriaxone—ALB—Folate Metabolism—SCARB1—kidney cancer	0.000251	0.0049	CbGpPWpGaD
Ceftriaxone—Pain—Doxorubicin—kidney cancer	0.000249	0.000333	CcSEcCtD
Ceftriaxone—GLUL—Transmission across Chemical Synapses—RAF1—kidney cancer	0.000246	0.00481	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—RYR1—kidney cancer	0.000246	0.0048	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—GPC3—kidney cancer	0.000241	0.0047	CbGpPWpGaD
Ceftriaxone—Feeling abnormal—Doxorubicin—kidney cancer	0.00024	0.000321	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000238	0.000319	CcSEcCtD
Ceftriaxone—GLUL—Metabolism—CA2—kidney cancer	0.000234	0.00457	CbGpPWpGaD
Ceftriaxone—Urticaria—Doxorubicin—kidney cancer	0.000232	0.00031	CcSEcCtD
Ceftriaxone—SLC22A11—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	0.000231	0.0045	CbGpPWpGaD
Ceftriaxone—Body temperature increased—Doxorubicin—kidney cancer	0.00023	0.000308	CcSEcCtD
Ceftriaxone—Abdominal pain—Doxorubicin—kidney cancer	0.00023	0.000308	CcSEcCtD
Ceftriaxone—GLUL—Metabolism—ALAD—kidney cancer	0.000228	0.00446	CbGpPWpGaD
Ceftriaxone—GLUL—Neuronal System—BRAF—kidney cancer	0.000226	0.00441	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—ST3GAL2—kidney cancer	0.000223	0.00435	CbGpPWpGaD
Ceftriaxone—SLC22A11—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	0.000223	0.00435	CbGpPWpGaD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—ANXA2—kidney cancer	0.000222	0.00434	CbGpPWpGaD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—ATP7B—kidney cancer	0.000222	0.00434	CbGpPWpGaD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—SLC5A3—kidney cancer	0.000222	0.00434	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—ALDH1A1—kidney cancer	0.000218	0.00425	CbGpPWpGaD
Ceftriaxone—Hypersensitivity—Doxorubicin—kidney cancer	0.000215	0.000287	CcSEcCtD
Ceftriaxone—SLC15A2—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	0.000213	0.00416	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PGK1—kidney cancer	0.000209	0.00408	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—SLC5A3—kidney cancer	0.000209	0.00408	CbGpPWpGaD
Ceftriaxone—ALB—Vitamin B12 Metabolism—SOD2—kidney cancer	0.000209	0.00407	CbGpPWpGaD
Ceftriaxone—Pruritus—Doxorubicin—kidney cancer	0.000206	0.000276	CcSEcCtD
Ceftriaxone—SLC15A2—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	0.000206	0.00402	CbGpPWpGaD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—SLC5A3—kidney cancer	0.000205	0.00401	CbGpPWpGaD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—ATP7B—kidney cancer	0.000205	0.00401	CbGpPWpGaD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—ANXA2—kidney cancer	0.000205	0.00401	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—LDHB—kidney cancer	0.000205	0.004	CbGpPWpGaD
Ceftriaxone—ALB—Selenium Micronutrient Network—SCARB1—kidney cancer	0.0002	0.0039	CbGpPWpGaD
Ceftriaxone—Diarrhoea—Doxorubicin—kidney cancer	0.000199	0.000267	CcSEcCtD
Ceftriaxone—SLC15A1—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	0.000198	0.00386	CbGpPWpGaD
Ceftriaxone—ALB—Selenium Micronutrient Network—PTGS1—kidney cancer	0.000198	0.00386	CbGpPWpGaD
Ceftriaxone—Dizziness—Doxorubicin—kidney cancer	0.000193	0.000258	CcSEcCtD
Ceftriaxone—SLC15A1—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	0.000191	0.00373	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—ANXA2—kidney cancer	0.00019	0.00372	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—ATP7B—kidney cancer	0.00019	0.00372	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—SLC5A3—kidney cancer	0.00019	0.00372	CbGpPWpGaD
Ceftriaxone—GLUL—Neuronal System—RAF1—kidney cancer	0.000189	0.00368	CbGpPWpGaD
Ceftriaxone—Vomiting—Doxorubicin—kidney cancer	0.000185	0.000248	CcSEcCtD
Ceftriaxone—Rash—Doxorubicin—kidney cancer	0.000184	0.000246	CcSEcCtD
Ceftriaxone—Dermatitis—Doxorubicin—kidney cancer	0.000184	0.000245	CcSEcCtD
Ceftriaxone—Headache—Doxorubicin—kidney cancer	0.000183	0.000244	CcSEcCtD
Ceftriaxone—GLUL—Metabolism—CA9—kidney cancer	0.000178	0.00347	CbGpPWpGaD
Ceftriaxone—SLC22A8—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	0.000176	0.00343	CbGpPWpGaD
Ceftriaxone—Nausea—Doxorubicin—kidney cancer	0.000173	0.000231	CcSEcCtD
Ceftriaxone—SLC22A8—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	0.00017	0.00331	CbGpPWpGaD
Ceftriaxone—ALB—Folate Metabolism—SOD2—kidney cancer	0.00017	0.00331	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—ANXA2—kidney cancer	0.000169	0.00331	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—ATP7B—kidney cancer	0.000169	0.00331	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—SLC5A3—kidney cancer	0.000169	0.00331	CbGpPWpGaD
Ceftriaxone—GLUL—Transmission across Chemical Synapses—MAPK1—kidney cancer	0.000169	0.0033	CbGpPWpGaD
Ceftriaxone—ALB—Platelet degranulation—IGF2—kidney cancer	0.000153	0.003	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—CRABP1—kidney cancer	0.000151	0.00295	CbGpPWpGaD
Ceftriaxone—SLC22A6—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	0.000147	0.00286	CbGpPWpGaD
Ceftriaxone—ALB—Response to elevated platelet cytosolic Ca2+—IGF2—kidney cancer	0.000146	0.00285	CbGpPWpGaD
Ceftriaxone—ALB—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	0.000145	0.00282	CbGpPWpGaD
Ceftriaxone—SLC22A6—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	0.000142	0.00277	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—ATP7B—kidney cancer	0.000141	0.00276	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—SLC5A3—kidney cancer	0.000141	0.00276	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—ANXA2—kidney cancer	0.000141	0.00276	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—ITPR2—kidney cancer	0.00014	0.00274	CbGpPWpGaD
Ceftriaxone—ALB—Selenium Micronutrient Network—SOD2—kidney cancer	0.000135	0.00263	CbGpPWpGaD
Ceftriaxone—GLUL—Neuronal System—MAPK1—kidney cancer	0.000129	0.00253	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—GSTT1—kidney cancer	0.000128	0.0025	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—ACHE—kidney cancer	0.000128	0.0025	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—RYR1—kidney cancer	0.000128	0.0025	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—SCARB1—kidney cancer	0.000121	0.00237	CbGpPWpGaD
Ceftriaxone—ALB—Vitamin B12 Metabolism—RELA—kidney cancer	0.000121	0.00235	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PTGS1—kidney cancer	0.00012	0.00234	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PSMD7—kidney cancer	0.000118	0.0023	CbGpPWpGaD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—SLC5A5—kidney cancer	0.000117	0.00229	CbGpPWpGaD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—SLC2A1—kidney cancer	0.000113	0.00221	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—L1CAM—kidney cancer	0.000112	0.00219	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—BCHE—kidney cancer	0.000112	0.00218	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—ITPR2—kidney cancer	0.000111	0.00216	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—SLC5A5—kidney cancer	0.00011	0.00215	CbGpPWpGaD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—SLC5A5—kidney cancer	0.000108	0.00211	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—SLC2A1—kidney cancer	0.000106	0.00208	CbGpPWpGaD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—SLC2A1—kidney cancer	0.000105	0.00204	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	0.000102	0.00199	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—SLC5A5—kidney cancer	0.0001	0.00196	CbGpPWpGaD
Ceftriaxone—ALB—Folate Metabolism—RELA—kidney cancer	9.81e-05	0.00191	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—SLC2A1—kidney cancer	9.7e-05	0.00189	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—SLC5A5—kidney cancer	8.93e-05	0.00174	CbGpPWpGaD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—ABCB1—kidney cancer	8.93e-05	0.00174	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—GSTP1—kidney cancer	8.87e-05	0.00173	CbGpPWpGaD
Ceftriaxone—ALB—Folate Metabolism—IL2—kidney cancer	8.83e-05	0.00172	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—SLC2A1—kidney cancer	8.63e-05	0.00168	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—ANXA2—kidney cancer	8.49e-05	0.00166	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—ABCB1—kidney cancer	8.4e-05	0.00164	CbGpPWpGaD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—ABCB1—kidney cancer	8.25e-05	0.00161	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—GSTM1—kidney cancer	8.15e-05	0.00159	CbGpPWpGaD
Ceftriaxone—ALB—Selenium Micronutrient Network—RELA—kidney cancer	7.79e-05	0.00152	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—CYP1A1—kidney cancer	7.73e-05	0.00151	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—ABCB1—kidney cancer	7.66e-05	0.0015	CbGpPWpGaD
Ceftriaxone—ALB—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	7.63e-05	0.00149	CbGpPWpGaD
Ceftriaxone—ALB—Selenium Micronutrient Network—PTGS2—kidney cancer	7.57e-05	0.00148	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—SLC5A5—kidney cancer	7.46e-05	0.00146	CbGpPWpGaD
Ceftriaxone—ALB—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	7.37e-05	0.00144	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—SLC5A3—kidney cancer	7.35e-05	0.00143	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—ATP7B—kidney cancer	7.35e-05	0.00143	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—ANXA2—kidney cancer	7.35e-05	0.00143	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—SLC2A1—kidney cancer	7.2e-05	0.00141	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—KCNMA1—kidney cancer	7.03e-05	0.00137	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—ABCB1—kidney cancer	6.81e-05	0.00133	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—IGF2—kidney cancer	6.81e-05	0.00133	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—ACY1—kidney cancer	6.55e-05	0.00128	CbGpPWpGaD
Ceftriaxone—ALB—Platelet degranulation—VEGFA—kidney cancer	6.44e-05	0.00126	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—GRB7—kidney cancer	6.14e-05	0.0012	CbGpPWpGaD
Ceftriaxone—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—kidney cancer	6.13e-05	0.0012	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—POMC—kidney cancer	5.76e-05	0.00113	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—ITPR2—kidney cancer	5.71e-05	0.00111	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—ABCB1—kidney cancer	5.68e-05	0.00111	CbGpPWpGaD
Ceftriaxone—ALB—Folate Metabolism—TP53—kidney cancer	5.67e-05	0.00111	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	5.59e-05	0.00109	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PDHB—kidney cancer	5.57e-05	0.00109	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CCBL1—kidney cancer	5.24e-05	0.00102	CbGpPWpGaD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—RAF1—kidney cancer	5.05e-05	0.000986	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	4.74e-05	0.000925	CbGpPWpGaD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—RAF1—kidney cancer	4.67e-05	0.000911	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PTGS2—kidney cancer	4.6e-05	0.000897	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GLIPR1—kidney cancer	4.54e-05	0.000887	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PPAT—kidney cancer	4.54e-05	0.000887	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	4.48e-05	0.000875	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	4.44e-05	0.000866	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—RAF1—kidney cancer	4.33e-05	0.000846	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—FH—kidney cancer	4.22e-05	0.000824	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—APRT—kidney cancer	4.22e-05	0.000824	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—IFNA1—kidney cancer	4.19e-05	0.000817	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	4.13e-05	0.000806	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PTEN—kidney cancer	4.01e-05	0.000783	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GPC3—kidney cancer	3.97e-05	0.000775	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—IFNA2—kidney cancer	3.9e-05	0.000761	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—SLC5A5—kidney cancer	3.88e-05	0.000757	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CA2—kidney cancer	3.86e-05	0.000754	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—RAF1—kidney cancer	3.85e-05	0.000752	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—ALAD—kidney cancer	3.76e-05	0.000735	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—RAF1—kidney cancer	3.75e-05	0.000731	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—SLC2A1—kidney cancer	3.74e-05	0.000731	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—ST3GAL2—kidney cancer	3.67e-05	0.000717	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—ALDH1A1—kidney cancer	3.59e-05	0.000701	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—IGF2—kidney cancer	3.51e-05	0.000685	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—SLC5A3—kidney cancer	3.44e-05	0.000672	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PGK1—kidney cancer	3.44e-05	0.000672	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—LDHB—kidney cancer	3.38e-05	0.000659	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—IL2—kidney cancer	3.36e-05	0.000656	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—RAF1—kidney cancer	3.22e-05	0.000628	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—ABCB1—kidney cancer	2.96e-05	0.000577	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CA9—kidney cancer	2.93e-05	0.000571	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	2.86e-05	0.000558	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—VEGFA—kidney cancer	2.86e-05	0.000557	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PIK3CA—kidney cancer	2.83e-05	0.000552	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—MAPK3—kidney cancer	2.7e-05	0.000527	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—MAPK1—kidney cancer	2.57e-05	0.000502	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CRABP1—kidney cancer	2.49e-05	0.000486	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—ITPR2—kidney cancer	2.31e-05	0.000452	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—PIK3CA—kidney cancer	2.23e-05	0.000435	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—POMC—kidney cancer	2.13e-05	0.000416	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GSTT1—kidney cancer	2.11e-05	0.000412	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—ACHE—kidney cancer	2.11e-05	0.000412	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—SCARB1—kidney cancer	2e-05	0.00039	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PTGS1—kidney cancer	1.98e-05	0.000386	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PSMD7—kidney cancer	1.94e-05	0.000378	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—RAF1—kidney cancer	1.93e-05	0.000377	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—BCHE—kidney cancer	1.84e-05	0.000359	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—SLC5A5—kidney cancer	1.82e-05	0.000354	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—SLC2A1—kidney cancer	1.75e-05	0.000342	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—IL2—kidney cancer	1.73e-05	0.000338	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.7e-05	0.000332	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—RAF1—kidney cancer	1.67e-05	0.000326	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.48e-05	0.00029	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—VEGFA—kidney cancer	1.47e-05	0.000287	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GSTP1—kidney cancer	1.46e-05	0.000285	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—MAPK3—kidney cancer	1.39e-05	0.000272	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—ABCB1—kidney cancer	1.38e-05	0.00027	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GSTM1—kidney cancer	1.34e-05	0.000262	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—MAPK1—kidney cancer	1.32e-05	0.000259	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CYP1A1—kidney cancer	1.27e-05	0.000249	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—KRAS—kidney cancer	1.25e-05	0.000244	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—PIK3CA—kidney cancer	1.15e-05	0.000224	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—TP53—kidney cancer	1.11e-05	0.000217	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	1.05e-05	0.000204	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—POMC—kidney cancer	9.5e-06	0.000185	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PTGS2—kidney cancer	7.57e-06	0.000148	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PTEN—kidney cancer	6.61e-06	0.000129	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PIK3CA—kidney cancer	4.66e-06	9.1e-05	CbGpPWpGaD
